March 16, 2022
Pharma companies are jittery about the course of upcoming debates on the “adjustment rate” and so-called “off-year” re-pricing - topics that have been put on hold in discussions towards Japan’s FY2022 reimbursement reform, a Jiho poll finds. A number of...read more